Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT03957954
Other study ID # V001
Secondary ID R01EY021797
Status Recruiting
Phase Phase 1
First received
Last updated
Start date September 30, 2020
Est. completion date May 31, 2024

Study information

Verified date December 2023
Source University of California, Los Angeles
Contact Clemence Bonnet, MD, PhD
Phone 310-825-6232
Email CBonnet@mednet.ucla.edu
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This phase I study will collect preliminary information on the activity and safety of cLSC. We will investigate the ability to manufacture and transplant cLSC onto the cornea successfully at the time of surgery (feasibility), and have cLSC begin to populate the ocular surface (efficacy) without serious adverse events (safety).


Description:

20 patients with severe to total Limbal Stem Cell Deficiency (LSCD) in one eye attributable to injury or ocular surgery. The first 5 eyes will receive the cLSCs to determine the feasibility and safety. Then the subsequent 15 eyes will be randomized into cLSC group and a scleral lens treatment (SCL) control group in a 2:1 ratio in blocks of 3 or 6 using a random number generator.


Recruitment information / eligibility

Status Recruiting
Enrollment 20
Est. completion date May 31, 2024
Est. primary completion date April 30, 2024
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Main inclusion Criteria: 1. Male or female =18 years of age. 2. Best corrected visual acuity in the affected eye of 20/200 or less. 3. Documentation of a LSCD diagnosis and the central cornea is affected. 4. Absence of lagophthalmos and eyelid abnormality 5. Adequate forniceal depth is = 5 mm. 6. LSCD fails to resolve by surgical treatments of the ocular surface during the previous 6 months of screening visit. 7. If the etiology of LSCD is due to chemical injury, a minimal interval of 1 year since the initial chemical injury is required. 8. A Schirmer test result at 5 minute of =5 mm of wetting. 9. Absence of active infectious keratitis in either eye at the Enrollment Visit. 10. Have a life expectancy = 2 years after enrollment. Main exclusion Criteria: 1. Pregnant, breastfeeding, or unwilling to practice birth control during participation in the study. 2. Presence of a condition or abnormality that in the opinion of the Investigator would compromise the safety of the patient or the quality of the data. 3. Exposure keratopathy or lagophthalmos of the study eye. 4. Persistent severe ocular surface inflammation and/or meibomian gland dysfunction 5. Chemical injury occurred less than 12 months ago. 6. Presence of ocular surface tumor. 7. Uncontrolled diabetes with last hemoglobin A1C (HgA1C) >8.5. 8. Presence of known allergies to any of the cLSC components. 9. Current participation in another simultaneous medical investigation or trial. 10. Unable to be compliant with or complete the requirements of the study.

Study Design


Intervention

Biological:
cLSC
Transplantation of cLSC
Device:
Scleral contact lens (SCL)
Scleral contact lens device (SCL) will be used to stabilize and improve ocular surface.

Locations

Country Name City State
United States University of California Los Angeles California

Sponsors (3)

Lead Sponsor Collaborator
University of California, Los Angeles California Institute for Regenerative Medicine (CIRM), National Eye Institute (NEI)

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Safety of cLSC Transplant pertaining to Infection and/or Corneal Perforation Safety assessed by incidence of Serious Adverse Events (SAEs) directly related to cLSC: infection and/or corneal perforation. 12 months for all participants
Primary Feasibility of cLSC Transplant pertaining to Manufacturing meeting Release Criteria Feasibility assessed by successful manufacturing of cLSC from biopsy that meets release criteria. 12 months for all participants
Primary Feasibility of cLSC Transplant pertaining to Manufacturing without Contamination Feasibility assessed by successful cLSC manufacturing without contamination. 12 months for all participants
Secondary Changes in the Area of Corneal Epithelial Defect Evaluate changes in the area of corneal epithelial defect (ED) or lack of ED. At 6 months and 12 months in both cLSC and the control groups
Secondary Changes in the Clinical Score Evaluate changes in the clinical score determined by slit lamp examination using fluorescein staining and confocal imaging. At 6 months and 12 months in both cLSC and the control groups
See also
  Status Clinical Trial Phase
Recruiting NCT05909735 - Treatment of LSCD With DM Phase 1
Completed NCT03594370 - Multiple Noninvasive Examination Modality to Evaluate the Severity of Ocular Surface Disorders
Recruiting NCT04021875 - The Effects of Autologous SLET
Recruiting NCT04021134 - The Effects of Allogeneic SLET
Completed NCT03226015 - Autologous Oral Mucosa Transplantation for Limbal Stem Cell Deficiency N/A
Recruiting NCT04995926 - Labial Mucosal Epithelium Grafting for Corneal Limbus Substitution N/A
Completed NCT05461469 - CDL Validation Study
Completed NCT02415218 - Transplantation of Autologous Oral Mucosal Epithelial Sheets for Limbal Stem-cell Deficiency Phase 1/Phase 2
Not yet recruiting NCT03884569 - Cultivated Limbal Epithelial Transplantation (CLET) for Limbal Stem Cell Deficiency (LSCD)